• The Scientist
    THLD with continued high short interest. Of all the stocks to short, this is one of the worst. Solid data. Potential to go up 10x quickly
    Reply (3)
    • HJStebbins: i like where your heads at ...i would like to see the chart mirror that of PCYC
    • The Scientist: Th-302 could be the breakthru drug that oncologists have been looking for. By targeting hypoxic niche, kills CSCs that promotes recurrence
    • The Scientist: Hypoxic CSCs r the 'untouchables' in oncology. Must b killed, but cannot get to them.